IgA Nephropathy Market Analysis, Size, Share & Growth Forecast 2026–2034

Sparsentan PROTECT Phase III 49.8 Versus 15.1 Percent Time-Averaged Proteinuria Reduction and 2-Year eGFR Slope Improvement Versus Irbesartan Has Established the Dual Endothelin and Angiotensin Receptor Antagonism as the Superior IgA Nephropathy Treatment Beyond RAAS Monotherapy.Travere Therapeutics's sparsentan, Calliditas Therapeutics's budesonide, Vera Therapeutics's atacicept, Otsuka Pharmaceutical's sibeprenlimab, Novartis's iptacopan, and Apellis Pharmaceuticals's pegcetacoplan represent six distinct mechanisms approaching or achieving approval in IgAN, reflecting the convergence of biological understanding of the galactose-deficient IgA1 four-hit hypothesis with precision medicine trial designs that have generated rapid clinical proof-of-concept across diverse immunological targets. The commercial opportunity in IgAN is estimated at USD 4-6 billion globally, driven by the approximately 150,000 US patients with proteinuria above 1 g per day despite RAAS blockade who meet criteria for advanced therapy. KDIGO 2021 IgAN guideline updates recommending proteinuria reduction below 0.5 g per day as the management target have established a high therapeutic bar that few patients achieve with RAAS blockade alone, defining the treatment gap that emerging therapies are designed to address.

Iptacopan APPLAUSE-IgAN 38.3 Percent Proteinuria Reduction From Oral Factor B Complement Alternative Pathway Inhibition on Top of Maximised RAAS Blockade Has Established the Oral Complement Inhibitor as the Approved IgAN Mechanism Targeting the Mesangial C3 Deposition Directly.Novartis's iptacopan APPLAUSE-IgAN Phase 3 demonstrated 38% UACR reduction from baseline at 9 months on background RAAS blockade and SGLT2 inhibitor, providing additive proteinuria reduction on top of guideline-mandatory background therapy that no currently approved IgAN therapy achieves. The alternative complement pathway's lectin pathway activation by galactose-deficient IgA1 immune complexes is the mechanistic step that deposits complement fragments in the glomerular mesangium and triggers inflammatory injury, and factor B inhibition blocks this pathway proximal to C3 activation without affecting classical pathway-dependent immune defence. The APPLAUSE-IgAN long-term data showing GFR stability at 3 years in iptacopan-treated patients versus continued decline in background-therapy-alone controls provides the first evidence of GFR trajectory modification in IgAN that translates proteinuria reduction to long-term renal function preservation.

Targeted-Release Budesonide Nefecon Tarpeyo 43 Percent Proteinuria Reduction From Distal Ileum Peyer's Patch Gd-IgA1 Mucosal Immunosuppression Has Established the 9-Month Oral Budesonide Course as the IgAN Treatment That Reduces the Galactose-Deficient IgA1 at the Site of Production.Vera Therapeutics's atacicept ORIGIN Phase 3 demonstrated 47% UACR reduction in IgAN at 36 weeks, among the largest proteinuria reductions reported in any IgAN trial, by blocking both BAFF and APRIL that are the survival signals for the galactose-deficient IgA1-producing mucosal plasma cells in the tonsillar and gut mucosa. The dual BAFF-APRIL blockade mechanism reduces circulating galactose-deficient IgA1 concentrations that are the starting point of the four-hit pathogenic cascade, providing a causal mechanism approach that targets the disease driver rather than downstream complement activation or mesangial inflammatory responses. The commercial differentiation of atacicept from complement inhibitors is the upstream mechanism that prevents galactose-deficient IgA1 production, potentially providing deeper and more sustained disease control by addressing the primary pathogenic species rather than managing its downstream consequences in the glomerulus.

For related market intelligence, see the Chronic Kidney Disease Market.